Spencer Pierce

Mr. Spencer Pierce

Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
JEJeffrey Ecker
Jeffrey Ecker
Greg KirchenbaumGreg Kirchenbaum
Greg Kirchenbaum
SPSpencer Pierce
Spencer Pierce
ASAmanda L. Skarlupka
Amanda L. Skarlupka
Rodrigo Bessa AbreuRodrigo Bessa Abreu
Rodrigo Bessa Abreu
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
Influenza viruses infect millions of people each year, resulting in significant morbidity and mortality in the human population. Therefore, generation of a universal influenza virus vaccine is an urgent need and would greatly benefit public health. Recombinant protein technology is an established vaccine platform and has resulted in several commercially available vaccines. Herein, we describe the approach for developing stable transfected human cell lines for the expression of recombinant influenza virus hemagglutinin (HA) and recombinant influenza virus neuraminidase (NA) proteins for the purpose of in vitro and in vivo vaccine development. HA and NA are the main surface glycoproteins on influenza virions and the major antibody targets. The benefits for using recombinant proteins for in vitro and in vivo assays include the ease of use, high level of purity and the ability to scale-up production. This work provides guidelines on how to produce and purify recombinant proteins produced in mammalian cell lines through either transient transfection or generation of stable cell lines from plasmid creation through the isolation step via Immobilized Metal Affinity Chromatography (IMAC). Collectively, the establishment of this pipeline has facilitated large-scale production of recombinant HA and NA proteins to high purity and with consistent yields, including glycosylation patterns that are very similar to proteins produced in a human host.

15 January 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
Greg KirchenbaumGreg Kirchenbaum
Greg Kirchenbaum
RARodrigo B. Abreu
Rodrigo B. Abreu
JEJeffrey W. Ecker
Jeffrey W. Ecker
SPSpencer Pierce
Spencer Pierce
TRTed Ross
Ted Ross
Computationally optimized broadly reactive Ags (COBRA) targeting H1 elicit a broad cross-reactive and cross-neutralizing Ab response against multiple H1N1 viral strains. To assess B cell breadth, Mus musculus (BALB/c) Ab-secreting cells elicited by a candidate COBRA hemagglutinin (HA) (termed P1) were compared with Ab-secreting cells elicited by historical H1N1 vaccine strains. In addition, to evaluate the Ab response elicited by P1 HA at increased resolution, a panel of P1 HA-specific B cell hybridomas was generated following immunization of mice with COBRA P1 and the corresponding purified mAbs were characterized for Ag specificity and neutralization activity. Both head- and stem-directed mAbs were elicited by the P1 HA Ag, with some mAbs endowed with Ab-dependent cell-mediated cytotoxicity activity. P1 HA-elicited mAbs exhibited a wide breadth of HA recognition, ranging from narrowly reactive to broadly reactive mAbs. Interestingly, we identified a P1 HA-elicited mAb (1F8) exhibiting broad hemagglutination inhibition activity against both seasonal and pandemic H1N1 influenza strains. Furthermore, mAb 1F8 recognized an overlapping, but distinct, epitope compared with other narrowly hemagglutination inhibition–positive mAbs elicited by the P1 or wild-type HA Ags. Finally, P1 HA-elicited mAbs were encoded by distinct H chain variable and L chain variable gene segment rearrangements and possessed unique CDR3 sequences. Collectively, the functional characterization of P1 HA-elicited mAbs sheds further insights into the underlying mechanism(s) of expanded Ab breadth elicited by a COBRA HA-based immunogen and advances efforts toward design and implementation of a more broadly protective influenza vaccine. Key Points Immunization with COBRA P1 elicits broadly HA-binding ASC. P1 HA-elicited mAbs have different binding and functional activities. The P1-elicited 1F8 mAb exhibits broad H1N1 binding and functional activity.

1 August 2018 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
Greg KirchenbaumGreg Kirchenbaum
Greg Kirchenbaum
JEJeffrey W. Ecker
Jeffrey W. Ecker
ABAnne-Gaelle Bebin-Blackwell
Anne-Gaelle Bebin-Blackwell
SPSpencer Pierce
Spencer Pierce
TRTed Ross
Ted Ross
Influenza viruses represent a threat to the world population. The currently available standard of care influenza vaccines are offered for each influenza season to prevent infection and spread of influenza viruses. Current vaccine formulations rely on using wild-type Ags, including the hemagglutinin (HA) and neuraminidase (NA) proteins as the primary immune targets of the vaccine. However, vaccine effectiveness varies from season to season, ranging from 10 to 75% depending on season and on age group studied. To improve rates of vaccine effectiveness, a new generation of computationally optimized broadly reactive Ags (COBRA)-based vaccines have been developed as a next-generation influenza vaccine. In this report, mice were intranasally, i.p., or i.m. primed with reassortant influenza viruses expressing different H1N1 COBRA HA proteins. These mice were subsequently boosted i.p. or i.m. with the same viruses. Sera collected from mice that were intranasally infected and i.p. boosted with COBRA-based viruses had broad anti-HA IgG binding, hemagglutination inhibition, and neutralizing activity against a panel of seasonal and pandemic H1N1 viruses. Mice immunized with viruses expressing a seasonal or pandemic H1N1 HA protein had antisera that recognized fewer viruses in the panel. Overall, COBRA-based HA proteins displayed on the surface of a virus elicited a breadth of Abs that recognized and neutralized historical H1N1 strains as well as more contemporary H1N1 viruses.

14 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TRTed Ross
Ted Ross
NGNaveen Gokanapudi
Naveen Gokanapudi
PGPan Ge
Pan Ge
HSHua Shi
Hua Shi
RRRobert A. Richardson
Robert A. Richardson
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
Notwithstanding the current SARS-CoV-2 pandemic, influenza virus infection still represents a global health concern in terms of hospitalizations and possible pandemic threats. The objective of next-generation influenza vaccines is not only to increase the breadth of response but also to improve the elicitation of an effective and robust immune response, especially in high-risk populations. To achieve this second objective, the administration of adjuvanted influenza vaccines has been considered. In this regard, the monitoring and characterization of the antibody response associated with the administration of adjuvanted vaccines has been evaluated in this study in order to shed light on the kinetic, magnitude and subclass usage of antibody secreting cells (ASCs) as well as of circulating antigen-specific serum antibodies. Specifically, we utilized the DBA/2J mouse model to assess the kinetic, magnitude and IgG subclass usage of the antibody response following an intramuscular (IM) or intraperitoneal (IP) immunization regimen with AddaVax-adjuvanted bivalent H1N1 and H3N2 computationally optimized broadly reactive antigen (COBRA) influenza recombinant hemagglutinins (rHAs). While the serological evaluation revealed a homogeneous kinetic of the antibody response, the detection of the ASCs through a FluoroSpot platform revealed a different magnitude, subclass usage and kinetic of the antigen-specific IgG secreting cells peaking at day 5 and day 9 following the IP and IM immunization, respectively.

13 November 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJohn Dzimianski
John Dzimianski
SPSpencer Pierce
Spencer Pierce
SOSara marie Orourke
Sara marie Orourke
IKIan Kunkel
Ian Kunkel
KDKevin Delgado-Cunningham
Kevin Delgado-Cunningham
RDRebecca DuBois
Rebecca DuBois
Protein subunit and mRNA vaccines encoding viral glycoprotein antigens fused to the bacteriophage T4 fibritintrimerization domain are increasingly being tested in human clinical trials. AREXVY and ABRYSVO ® , subunit vaccines composed of respiratory syncytial virus (RSV) prefusion F glycoprotein(s) fused to Foldon, are now FDA-approved and regularly administered. However, administration of vaccine antigens containing the Foldon domain has the potential to elicit off-target antibody responses. Here, we demonstrate that protein subunit vaccine antigens RSV F Foldon and influenza hemagglutinin (HA) Foldon elicit antibodies against the Foldon domain. To dampen Foldon-induced antibody responses, we engineered influenza computationally optimized broadly reactive antigen (COBRA) HA proteins with N-glycosylation motif mutations at three different sites in Foldon. Mass spectrometry analyses confirmed partial occupancy of N-glycosylation modifications at two of the three intended sites. Two of the three COBRA HA Foldon mutant antigens demonstrated reduced binding by anti-Foldon monoclonal and polyclonal antibodies compared to the wild-type COBRA HA Foldon. However, mice immunized with the COBRA HA Foldon mutant antigens did not have a significant reduction in the elicitation of anti-Foldon antibodies. Further analysis suggested that some of the observed differences in antibody binding to mutant Foldon antigens can be attributed to differences in protein sequence alone. Altogether, these data suggest that while the N-glycosylation modifications may partially shield the Foldon from reactive antibodies, this shielding does not significantly reduce its immunogenicity in a naïve setting. Importantly, these data highlight that the Foldon trimerization domain is immunogenic, which should be considered during clinical trials of vaccines that contain Foldon.